Clinical Trials and Stages of
Drug Development
-
![]()
Notable is Launching a New Era of Precision Medicine
ButtonTheIr cutting-edge technology leverages genomics and AI to provide personalized treatment solutions, revolutionizing disease diagnosis and treatment. Discover the future of medicine with Notable Labs' advanced healthcare technologies.
Latest Insignts
By Dr. Ahmed Donia
•
August 13, 2024
Notable Labs is revolutionizing cancer treatment with its Predictive Precision Medicine Platform (PPMP), which simulates therapies and predicts patient responses with 95% accuracy. This groundbreaking technology leverages artificial intelligence and machine learning to generate extensive datasets from patient samples, enabling tailored treatments for each patient. In pediatric leukemia, precision diagnostics like next-generation sequencing enhance risk stratification, targeted therapies, and personalized treatment plans, potentially improving survival rates and quality of life. Notable's PPMP has shown success in predicting drug responses, such as achieving 100% accuracy in predicting clinical responses to venetoclax with decitabine in Acute Myeloid Leukemia. Rather than commercializing PPMP as a standalone product, Notable focuses on using its capabilities to enhance drug development, fast-track clinical trials, reduce risks, and improve patient outcomes by targeting responsive populations.
By Dr. Anjaney Kothari
•
August 13, 2024
Combination therapy in cancer treatment involves using multiple therapeutic agents to target various aspects of the disease, offering improved patient outcomes. Notable Labs is leading advancements in this field, exemplified by its collaboration with Syros Pharmaceuticals to develop a predictive test for a combination therapy against non-acute promyelocytic leukemia (APL) acute myeloid leukemia (AML). Notable’s Predictive Precision Medicine Platform (PPMP) uses ex vivo drug sensitivity screening to predict patient responses to treatments, enhancing the effectiveness and safety of combination therapies. Despite current commercial challenges, Notable is focused on refining and expanding its technology, ensuring seamless integration into healthcare systems.
By Conor Prendergast
•
August 13, 2024
Notable Labs is a biotech startup revolutionizing cancer treatment through its innovative Precision Predictive Medicine Platform (PMPP), leveraging data and technology to identify the most effective therapies for each patient. Founded by Matthew De Silva after his father's glioblastoma diagnosis, Notable Labs combines De Silva's finance background with the medical expertise of CEO Dr. Thomas Bock. The team includes esteemed professionals like Dr. Joseph Wagner, Dr. Glenn Michelson, and Scott McPherson, who collectively bring decades of experience in biotech, clinical trials, and financial strategy. Notable Labs partners with renowned hospitals and employs cutting-edge drug screening technology to provide personalized, data-driven treatment plans, significantly improving patient outcomes. With a dedicated and diverse team, Notable Labs stands at the forefront of precision oncology, offering hope and new possibilities for cancer patients worldwide.
By Divya Narasimhan
•
August 13, 2024
Notable Labs' Predictive Precision Medicine Platform (PPMP) is revolutionizing pediatric leukemia treatment by leveraging advanced machine learning to predict the most effective therapies with 95% accuracy, as demonstrated in a Stanford study. This innovative approach tailors treatments to each patient's unique cancer profile, significantly improving outcomes for rare and aggressive leukemia types like pediatric acute myeloid leukemia (pAML) and juvenile myelomonocytic leukemia (JMML). Notable Labs' collaborations with leading institutions and use of high-throughput screening have enabled the rapid identification of effective drug combinations and personalized therapies, providing hope for better survival rates and quality of life for young cancer patients. With its commitment to refining precision medicine and expanding its applications, Notable Labs is poised to transform cancer care, ensuring that every child receives the best possible treatment.
By Fabian Goguta
•
August 13, 2024
Predictive precision medicine, which predicts the most effective treatment for each patient, is revolutionizing cancer care. Notable Labs leverages this approach to improve cancer treatment by identifying optimal therapies for individual patients. According to a 2020 Stanford study, Notable's Predictive Medicine Platform (PMP) accurately predicted patient response to interventions in over 85% of cases. This technology analyzes how cancer cells respond to various treatments using flow cytometry and machine learning algorithms, providing actionable insights quickly. Notable Labs' collaborations with leading institutions have demonstrated significant success in treating pediatric leukemia, particularly rare and aggressive forms like pAML and JMML. By partnering with renowned medical centers and advancing the use of predictive diagnostics, Notable Labs is at the forefront of transforming pediatric oncology and improving outcomes for young patients.
By Kathleen Mackay
•
July 29, 2024
Notable Labs is transforming cancer treatment with its innovative combination therapy approach. By leveraging its Predictive Precision Medicine Platform (PPMP), Notable identifies optimal drug combinations tailored to individual patients. This methodology aims to reduce the development of resistant cancer cells and allows each drug to be used at its best dosage without intolerable side effects. The platform has shown impressive predictive accuracy in clinical trials, particularly for pediatric leukemia. Notable's commitment to precision medicine offers new hope for patients with high unmet medical needs, driving better treatment outcomes and enhancing quality of life.
By Scott Smith
•
July 29, 2024
Notable Labs is revolutionizing cancer treatment with its innovative approach to combination therapy, which targets multiple cancer pathways simultaneously. Their Predictive Precision Medicine Platform (PPMP) leverages advanced data analysis and machine learning to identify the most effective drug combinations for individual patients. By using high-throughput screening and bio-simulation, Notable Labs accelerates drug development, reduces costs, and improves clinical trial success rates. This approach promises significant improvements in patient outcomes, particularly for pediatric leukemia, by providing personalized, effective treatments and minimizing side effects.
By Ayushi Hisaria
•
July 29, 2024
Notable Labs' cutting-edge diagnostic technology, boasting a 95% prediction accuracy per a Stanford study, is set to revolutionize pediatric leukemia treatment by identifying the most effective therapies. Their mission centers on advancing precision diagnostics to enhance therapy efficacy for young patients. Utilizing high-throughput screening and machine learning, Notable's platform offers tailored treatment plans, significantly improving outcomes for rare and aggressive forms of leukemia. This approach holds promise for personalized medicine, ensuring each child receives optimal, life-saving care.
By Syeda Abeer Iqbal
•
July 29, 2024
Notable Labs is transforming pediatric leukemia treatment with its Predictive Precision Medicines Platform (PPMP), which boasts a 97% predictive precision. This platform rapidly identifies the most effective treatments for individual patients, significantly reducing the time and cost of cancer therapy. Notable Labs focuses on personalized medicine, combining high-throughput screening and machine learning to predict patient responses and tailor treatments accordingly. Their innovative approach has shown promising results in clinical validation studies, offering new hope for improving outcomes in pediatric leukemia.
By Daniel Ferry
•
July 29, 2024
Notable Labs is a clinical-stage precision oncology company developing new cancer therapies identified by its Predictive Medicine Platform (PMP), today announced progress for the Phase 2 volasertib program following receNotable Labs is a clinical-stage precision oncology company developing new cancer therapies identified by its Predictive Medicine Platform (PMP), today announced progress for the Phase 2 volasertib program following receipt of “Clearance to Proceed” from the FDA and agreement on the dosing plan for its Phase 2 clinical trial. With trial start-up activities launched in the first quarter of this year, Notable intends to initiate enrollment in the Phase 2 study for PMP-enabled development of volasertib for relapsed refractory (R/R) acute myeloid leukemia (AML) in the coming months.ipt of “Clearance to Proceed” from the FDA and agreement on the dosing plan for its Phase 2 clinical trial. With trial start-up activities launched in the first quarter of this year, Notable intends to initiate enrollme
Latest Insignts
By Dr. Ahmed Donia
•
August 13, 2024
Notable Labs is revolutionizing cancer treatment with its Predictive Precision Medicine Platform (PPMP), which simulates therapies and predicts patient responses with 95% accuracy. This groundbreaking technology leverages artificial intelligence and machine learning to generate extensive datasets from patient samples, enabling tailored treatments for each patient. In pediatric leukemia, precision diagnostics like next-generation sequencing enhance risk stratification, targeted therapies, and personalized treatment plans, potentially improving survival rates and quality of life. Notable's PPMP has shown success in predicting drug responses, such as achieving 100% accuracy in predicting clinical responses to venetoclax with decitabine in Acute Myeloid Leukemia. Rather than commercializing PPMP as a standalone product, Notable focuses on using its capabilities to enhance drug development, fast-track clinical trials, reduce risks, and improve patient outcomes by targeting responsive populations.
By Dr. Anjaney Kothari
•
August 13, 2024
Combination therapy in cancer treatment involves using multiple therapeutic agents to target various aspects of the disease, offering improved patient outcomes. Notable Labs is leading advancements in this field, exemplified by its collaboration with Syros Pharmaceuticals to develop a predictive test for a combination therapy against non-acute promyelocytic leukemia (APL) acute myeloid leukemia (AML). Notable’s Predictive Precision Medicine Platform (PPMP) uses ex vivo drug sensitivity screening to predict patient responses to treatments, enhancing the effectiveness and safety of combination therapies. Despite current commercial challenges, Notable is focused on refining and expanding its technology, ensuring seamless integration into healthcare systems.
By Conor Prendergast
•
August 13, 2024
Notable Labs is a biotech startup revolutionizing cancer treatment through its innovative Precision Predictive Medicine Platform (PMPP), leveraging data and technology to identify the most effective therapies for each patient. Founded by Matthew De Silva after his father's glioblastoma diagnosis, Notable Labs combines De Silva's finance background with the medical expertise of CEO Dr. Thomas Bock. The team includes esteemed professionals like Dr. Joseph Wagner, Dr. Glenn Michelson, and Scott McPherson, who collectively bring decades of experience in biotech, clinical trials, and financial strategy. Notable Labs partners with renowned hospitals and employs cutting-edge drug screening technology to provide personalized, data-driven treatment plans, significantly improving patient outcomes. With a dedicated and diverse team, Notable Labs stands at the forefront of precision oncology, offering hope and new possibilities for cancer patients worldwide.
By Divya Narasimhan
•
August 13, 2024
Notable Labs' Predictive Precision Medicine Platform (PPMP) is revolutionizing pediatric leukemia treatment by leveraging advanced machine learning to predict the most effective therapies with 95% accuracy, as demonstrated in a Stanford study. This innovative approach tailors treatments to each patient's unique cancer profile, significantly improving outcomes for rare and aggressive leukemia types like pediatric acute myeloid leukemia (pAML) and juvenile myelomonocytic leukemia (JMML). Notable Labs' collaborations with leading institutions and use of high-throughput screening have enabled the rapid identification of effective drug combinations and personalized therapies, providing hope for better survival rates and quality of life for young cancer patients. With its commitment to refining precision medicine and expanding its applications, Notable Labs is poised to transform cancer care, ensuring that every child receives the best possible treatment.
By Fabian Goguta
•
August 13, 2024
Predictive precision medicine, which predicts the most effective treatment for each patient, is revolutionizing cancer care. Notable Labs leverages this approach to improve cancer treatment by identifying optimal therapies for individual patients. According to a 2020 Stanford study, Notable's Predictive Medicine Platform (PMP) accurately predicted patient response to interventions in over 85% of cases. This technology analyzes how cancer cells respond to various treatments using flow cytometry and machine learning algorithms, providing actionable insights quickly. Notable Labs' collaborations with leading institutions have demonstrated significant success in treating pediatric leukemia, particularly rare and aggressive forms like pAML and JMML. By partnering with renowned medical centers and advancing the use of predictive diagnostics, Notable Labs is at the forefront of transforming pediatric oncology and improving outcomes for young patients.
By Kathleen Mackay
•
July 29, 2024
Notable Labs is transforming cancer treatment with its innovative combination therapy approach. By leveraging its Predictive Precision Medicine Platform (PPMP), Notable identifies optimal drug combinations tailored to individual patients. This methodology aims to reduce the development of resistant cancer cells and allows each drug to be used at its best dosage without intolerable side effects. The platform has shown impressive predictive accuracy in clinical trials, particularly for pediatric leukemia. Notable's commitment to precision medicine offers new hope for patients with high unmet medical needs, driving better treatment outcomes and enhancing quality of life.
By Scott Smith
•
July 29, 2024
Notable Labs is revolutionizing cancer treatment with its innovative approach to combination therapy, which targets multiple cancer pathways simultaneously. Their Predictive Precision Medicine Platform (PPMP) leverages advanced data analysis and machine learning to identify the most effective drug combinations for individual patients. By using high-throughput screening and bio-simulation, Notable Labs accelerates drug development, reduces costs, and improves clinical trial success rates. This approach promises significant improvements in patient outcomes, particularly for pediatric leukemia, by providing personalized, effective treatments and minimizing side effects.
By Ayushi Hisaria
•
July 29, 2024
Notable Labs' cutting-edge diagnostic technology, boasting a 95% prediction accuracy per a Stanford study, is set to revolutionize pediatric leukemia treatment by identifying the most effective therapies. Their mission centers on advancing precision diagnostics to enhance therapy efficacy for young patients. Utilizing high-throughput screening and machine learning, Notable's platform offers tailored treatment plans, significantly improving outcomes for rare and aggressive forms of leukemia. This approach holds promise for personalized medicine, ensuring each child receives optimal, life-saving care.
By Syeda Abeer Iqbal
•
July 29, 2024
Notable Labs is transforming pediatric leukemia treatment with its Predictive Precision Medicines Platform (PPMP), which boasts a 97% predictive precision. This platform rapidly identifies the most effective treatments for individual patients, significantly reducing the time and cost of cancer therapy. Notable Labs focuses on personalized medicine, combining high-throughput screening and machine learning to predict patient responses and tailor treatments accordingly. Their innovative approach has shown promising results in clinical validation studies, offering new hope for improving outcomes in pediatric leukemia.
By Daniel Ferry
•
July 29, 2024
Notable Labs is a clinical-stage precision oncology company developing new cancer therapies identified by its Predictive Medicine Platform (PMP), today announced progress for the Phase 2 volasertib program following receNotable Labs is a clinical-stage precision oncology company developing new cancer therapies identified by its Predictive Medicine Platform (PMP), today announced progress for the Phase 2 volasertib program following receipt of “Clearance to Proceed” from the FDA and agreement on the dosing plan for its Phase 2 clinical trial. With trial start-up activities launched in the first quarter of this year, Notable intends to initiate enrollment in the Phase 2 study for PMP-enabled development of volasertib for relapsed refractory (R/R) acute myeloid leukemia (AML) in the coming months.ipt of “Clearance to Proceed” from the FDA and agreement on the dosing plan for its Phase 2 clinical trial. With trial start-up activities launched in the first quarter of this year, Notable intends to initiate enrollme